Drug Profile
ASN 004 - Asana BioSciences
Alternative Names: ASN 004; Dolaflexin® ADC - Asana BioSciences; Fleximer® - ADC - Endo Pharmaceuticals/Mersana TherapeuticsLatest Information Update: 23 Jun 2022
Price :
$50
*
At a glance
- Originator Endo Pharmaceuticals
- Developer Asana BioSciences
- Class Antineoplastics; Cancer vaccines; Depsipeptides; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Aug 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04410224)
- 28 Mar 2021 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 04 Feb 2021 Asana BioSciences plans a first-in-human phase I trial for ASN 004 for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in August 2021 (NCT04410224)